[1]
Uchida Y, Minoshima S, Kawata T, et al. Diagnostic value of FDG PET and salivary gland scintigraphy for parotid tumors. Clin Nucl Med 2005; 30(3): 170-6.
[2]
Seo YL, Yoon DY, Baek S, et al. Incidental focal FDG uptake in the parotid glands on PET/CT in patients with head and neck malignancy. Eur Radiol 2015; 25(1): 171-7.
[3]
Bothe C, Fernandez A, Garcia J, et al. Parotid incidentaloma identified by positron emission/computed tomography: When to consider diagnoses other than warthin tumor. Int Arch Otorhinolaryngol 2015; 19(2): 112-5.
[4]
Horiuchi M, Yasuda S, Shohtsu A, Ide M. Four cases of Warthin’s tumor of the parotid gland detected with FDG PET. Ann Nucl Med 1998; 12(1): 47-50.
[5]
Klijanienko J, Petras S, De Bosschere L, Paulmier B, Le Tourneau C, Rodriguez J. False-positive FDG PET/CT uptake in Warthin tumor in head and neck oncological patients confirmed by a fine needle aspiration. Diagn Cytopathol 2012; 40(3): 282-4.
[6]
Fang T, Zhu J, Chuan L, Zhao W, Liang Y, Wang S. DifferentialDiagnosis of Warthin’s tumor complicated with lung adenocarcinoma by 18F- FDG PET/CT imaging and radioisotope scanning with Tc-99m pertechnetate: A case report and literature review. Chin J Cancer Res 2010; 22(2): 163-6.
[7]
Shah VN, Branstetter BF. Oncocytoma of the parotid gland: A potential false-positive finding on 18F-FDG PET. AJR 2007; 189(4): W212-14.
[8]
Koch A, Lang SA, Wild PJ, et al. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells. Oncotarget 2015; 6(32): 32748-60.
[9]
Mabray MC, Behr SC, Naeger DM, Flavell RR, Glastonbury CM. Predictors of pathologic outcome of focal FDG uptake in the parotid gland identified on whole-body FDG PET imaging. Clin Imaging 2015; 39(6): 1073-9.
[10]
Bron LP, Traynor SJ, McNeil EB, O’Brien CJ. Primary and metastatic cancer of the parotid: Comparison of clinical behavior in 232 cases. Laryngoscope 2003; 113: 1070-5.
[11]
Pomar Blanco P, Martín Villares C, San Román Carbajo J. TapiaRisueño M, Fernández Pello M. Metastasis to the parotid gland. Acta Otorrinolaringol Esp 2006; 57(1): 47-50.
[12]
P. Suton. I. Luksˇic´, D. Mu¨ller, M. Virag: Lymphatic drainage patterns of head and neck cutaneous melanoma: Doesprimary melanoma site correlate with anatomic distribution of pathologically involved lymph nodes? Int J Oral Maxillofac Surg 2012; 41: 413-20.
[13]
Rassekh CH, Cost JL, Hogg JP, Hurst MK, Marano GD, Ducatman BS. Positron emission tomography in Warthin’s tumor mimicking malignancy impacts the evaluation of head and neck patients. Am J Otolaryngol 2015; 36(2): 259-63.
[14]
Basu S, Houseni M, Alavi A. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management. Nucl Med Commun 2008; 29(4): 367-73.
[15]
Lee SK, Rho BH, Won KS. Parotid incidentaloma identified by combined 18F-fluorodeoxyglucose whole-body positron emissiontomography and computed tomography: Findings at gray scale and power Doppler ultrasonography and ultrasound-guided fine-needle aspiration biopsy or core-needle biopsy. Eur Radiol 2009; 19(9): 2268-74.
[16]
Toriihara A, Nakamura S, Kubota K, Makino T, Okochi K, Shibuya H. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors? AJR Am J Roentgenol 2013; 201(3): 639-44.
[17]
Ozawa N, Okamura T, Koyama K, et al. Retrospective review: Usefulness of a number of imaging modalities including CT, MRI, technetium-99m pertechnetate scintigraphy, gallium-67 scintigraphy and F-18-FDG PET in the differentiation of benign from malignant parotid masses. Radiat Med 2006; 24(1): 41-9.
[18]
Burgess AN, Serpell JW. Parotidectomy: Preoperative investigations and outcomes in a single surgeon practice. ANZ J Surg 2008; 78(9): 791-3.
[19]
Dăguci L, Simionescu C, Stepan A, Munteanu C, Dăguci C, Bătăiosu M. Warthin tumor-morphological study of the stromalcompartment. Rom J Morphol Embryol 2011; 52(4): 1319-23.
[20]
Chedid HM, Rapoport A, Aikawa KF. MenezesAdos S, Curioni OA. Warthin’s tumor of the parotid gland: Study of 70 cases. Rev Col Bras Cir 2011; 38(2): 90-4.
[21]
Teymoortash A, Krasnewicz Y, Werner JA. Clinical features of cystadenol ymphoma (Warthin’s tumor) of the parotid gland: A retrospective comparative study of 96 cases. Oral Oncol 2006; 42(6): 569-73.
[22]
Maiorano E, LoMuzio L, Favia G, Piattelli A. Warthin’s tumour: A study of 78 cases with emphasis on bilaterality, multifocality and association with other malignancies. Oral Oncol 2002; 38(1): 35-40.
[23]
O’Neill ID. New insights into the nature of Warthin’s tumour. J Oral Pathol Med 2009; 38(1): 145-9.
[24]
Takezawa K, Jackson C, Gnepp DR, King TC. Molecular characterization of Warthin tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85(5): 569-75.
[25]
Aguirre JM, Echebarría MA, Martínez-Conde R, Rodriguez C, Burgos JJ, Rivera JM. Warthin tumor. A new hypothesis concerning its development. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85(1): 60-3.
[26]
Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 2004; 45(6): 930-2.
[27]
Horiuchi C, Tsukuda M, Taguchi T, Ishiguro Y, Okudera K, Inoue T. Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl Med 2008; 22(8): 693-8.
[28]
Teymoortash A, Schrader C, Shimoda H, Kato S, Werner JA. Evidence of lymphangiogenesis in Warthin’s tumor of the parotid gland. Oral Oncol 2007; 43(6): 614-8.
[29]
White CK, Williams KA, Rodriguez-Figueroa J, Langer CJ. Warthin’s tumors and their relationship to lung cancer. Cancer Invest 2015; 33(1): 1-5.
[30]
Treglia G, Bertagna F, Sadeghi R, Muoio B, Giovanella L. Prevalence and risk of malignancy of focal incidental uptake detected by fluorine-18-fluorodeoxyglucose positron emission tomography in the parotid gland: A meta-analysis. Eur Arch Otorhinolaryngol 2015; 272(12): 3617-26.
22
1